Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2021 / Cilt: 29 - Sayı: 2

Evaluation of prognostic factors in lung cancers with surgical complete response after induction treatment

İndüksiyon tedavisi sonrasında cerrahi patolojik tam yanıt alınan akciğer kanserlerinde prognostik faktörlerin değerlendirilmesi

Pages
201–211
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The five-year overall survival rate was 61.2%, and the disease-free survival rate was 55.1%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: This study aims to evaluate long-term results of induction treatment and to investigate prognostic factors affecting survival in non-small cell lung cancer patients with a pathological complete response.
📊
Key Findings & Data:Methods: Between January 2010 and December 2017, a total of 39 patients (38 males, 1 female; mean age: 56.2±8.3 years; range, 38 to 77 years) having locally advanced (IIIA-IIIB) non-small cell lung cancer who were given induction treatment and underwent surgery after induction treatment and had a pathological complete response were retrospectively analyzed.
💡
Conclusion & Impact:The five-year overall survival rate was 61.2%, and the disease-free survival rate was 55.1%.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: This study aims to evaluate long-term results of induction treatment and to investigate prognostic factors affecting survival in non-small cell lung cancer patients with a pathological complete response. Methods: Between January 2010 and December 2017, a total of 39 patients (38 males, 1 female; mean age: 56.2±8.3 years; range, 38 to 77 years) having locally advanced (IIIA-IIIB) non-small cell lung cancer who were given induction treatment and underwent surgery after induction treatment and had a pathological complete response were retrospectively analyzed. Survival rates of the patients and prognostic factors of survival were analyzed. Results: Clinical staging before induction treatment revealed Stage IIB, IIIA, and IIIB disease in three (7.7%), 26 (66.7%), and 10 (25.6%) patients, respectively. The five-year overall survival rate was 61.2%, and the disease-free survival rate was 55.1%. In nine (23.1%) patients, local and distant recurrences were detected in the postoperative period. Conclusion: In patients with locally advanced non-small cell lung cancer undergoing surgery after induction treatment, the rates of pathological complete response are at considerable levels. In these patients, the five-year overall survival is quite satisfactory and the most important prognostic factor affecting overall survival is the presence of single-station N2.

Özet

Amaç: Bu çalışmada, patolojik tam yanıt veren küçük hücreli dışı akciğer kanserli hastalarda indüksiyon tedavisinin uzun dönem sonuçları değerlendirildi ve sağkalımı etkileyen prognostik faktörler araştırıldı. Çalışma planı: Ocak 2010 ve Aralık 2017 tarihleri arasında indüksiyon tedavisi verilen ve indüksiyon tedavisinden sonra ameliyat edilen ve patolojik tam yanıt veren ileri evre (IIIA-IIIB) küçük hücreli dışı akciğer kanseri olan toplam 39 hasta (38 erkek, 1 kadın; ort. yaş: 56.2±8.3 yıl; dağılım 38-77 yıl) retrospektif olarak incelendi. Hastaların sağkalım oranları ve sağkalımın prognostik faktörleri değerlendirildi. Bulgular: İndüksiyon tedavisi öncesi klinik evrelemede üç (%7.7) hastada Evre IIB, 26 (%66.7) hastada Evre IIIA, ve 10 (%25.6) hastada Evre IIIB hastalık izlendi. Beş yıllık sağkalım oranı %61.2 olup, hastalıksız sağkalım oranı %55.1 idi. Dokuz (%23.1) hastada, ameliyat sonrası dönemde lokal nüks veya uzak nüks saptandı. Sonuç: İndüksiyon tedavisi sonrası ameliyat edilen lokal ileri evre küçük hücreli dışı akciğer kanserli hastalarda, patolojik tam yanıt oranı azımsanamayacak düzeydedir. Bu hastalarda beş yıllık genel sağkalım oldukça memnun edici olup, genel sağkalımı etkileyen en önemli prognostik faktör tek istasyon N2 varlığıdır.

🔖

Cite This Article

CANSEVER, L., SEZEN, C. B., METİN, M., AKER, C., ÖLÇMEN, A., ERDOĞU, V., SAYDAM, Ö., DOĞRU, M. V. (2022). Evaluation of prognostic factors in lung cancers with surgical complete response after induction treatment. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 29 - Sayı: 2, 201–211. https://ajindex.com/articles/423589

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Sezen CB, Aksoy Y, Sonmezoglu Y, Citak N, Saydam O, Metin M. Prognostic factors for survival in patients with completely resected pN2 non-small-cell lung cancer. Acta Chir Belg 2021;121:23-9
  2. Song WA, Zhou NK, Wang W, Chu XY, Liang CY, Tian XD, et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: An updated meta-analysis of 13 randomized control trials. J Thorac Oncol 2010;5:510-6
  3. Akyıl M, Tezel Ç, Tokgöz Akyıl F, Gürer D, Evman S, Alpay L, et al. Prognostic significance of pathological complete response in non-small cell lung cancer following neoadjuvant treatment. Turk Gogus Kalp Dama 2020;28:166-74
  4. Paul S, Mirza F, Port JL, Lee PC, Stiles BM, Kansler AL, et al. Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: Age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. J Thorac Cardiovasc Surg 2011;141:48-58
  5. Higgins K, Chino JP, Marks LB, Ready N, D'Amico TA, Clough RW, et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2009;75:1462-7
  6. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: Results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007;369:1929-37
  7. Eberhardt WE, Albain KS, Pass H, Putnam JB, Gregor A, Assamura H, et al. Induction treatment before surgery for nonsmall cell lung cancer. Lung Cancer 2003;42 Suppl 1:S9-14
  8. Machtay M, Lee JH, Stevenson JP, Shrager JB, Algazy KM, Treat J, et al. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: Long-term results and associations with pathologic response. J Thorac Cardiovasc Surg 2004;127:108-13
  9. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: Who returns to the surgical arena and who survives. Ann Thorac Surg 2008;86:912-20
  10. Lococo F, Cesario A, Margaritora S, Dall'Armi V, Mattei F, Romano R, et al. Long-term results in patients with pathological complete response after induction radiochemotherapy followed by surgery for locally advanced non-small-cell lung cancer. Eur J Cardiothorac Surg 2013;43:e71-81
  11. Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R,